Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).

Publication

Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).

Journal Paper/Review - Dec 30, 2022

Amaral Teresa, Sinnberg Tobias, Chatziioannou Eftychia, Niessner Heike, Leiter Ulrike, Keim Ulrike, Forschner Andrea, Dwarkasing Jvalini, Tjien-Fooh Félicia, Wever Renske, Flatz Lukas, Eggermont Alexander, Forchhammer Stephan

Citation

Amaral T, Sinnberg T, Chatziioannou E, Niessner H, Leiter U, Keim U, Forschner A, Dwarkasing J, Tjien-Fooh F, Wever R, Flatz L, Eggermont A, Forchhammer S. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Eur J Cancer 2022; 182:155-162.

Type

Journal Paper/Review (English)

Journal

Eur J Cancer 2022; 182

Publication Date

Dec 30, 2022

Issn Electronic

1879-0852

Pages

155-162

Brief description/objective

Patients with cutaneous melanoma stage I/IIA disease are currently not eligible for adjuvant therapy, despite their risk for relapses and death. This study validates the ability of a model combining clinicopathologic factors with gene expression profiling (CP-GEP) to identify patients at high risk for disease recurrence in stage I/II and subgroup stage I/IIA.